Lunai Bioworks (LNAI) Competitors

$0.26 -0.02 (-7.01%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$0.25 0.00 (-1.24%)

As of 05/15/2026 07:58 PM Eastern

LNAI vs. VIRI, SNSE, TVGN, SNTI, and PLRZ

Should you buy Lunai Bioworks stock or one of its competitors? MarketBeat compares Lunai Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lunai Bioworks include Virios Therapeutics (VIRI), Sensei Biotherapeutics (SNSE), Tevogen Bio (TVGN), Senti Biosciences (SNTI), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry.

How does Lunai Bioworks compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, Lunai Bioworks had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for Lunai Bioworks and 1 mentions for Virios Therapeutics. Lunai Bioworks' average media sentiment score of 0.26 beat Virios Therapeutics' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lunai Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Virios Therapeutics' return on equity of -130.33% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Lunai Bioworks	N/A	-1,243.45%	-360.31%

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	$0.05	5.14

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lunai Bioworks beats Virios Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Lunai Bioworks compare to Sensei Biotherapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Sensei Biotherapeutics had 14 more articles in the media than Lunai Bioworks. MarketBeat recorded 19 mentions for Sensei Biotherapeutics and 5 mentions for Lunai Bioworks. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Lunai Bioworks' score of 0.26 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lunai Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	$0.05	5.14
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

Sensei Biotherapeutics' return on equity of -83.59% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-360.31%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

Lunai Bioworks has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

Sensei Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 95.79%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sensei Biotherapeutics beats Lunai Bioworks on 9 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Tevogen Bio and Tevogen Bio both had 5 articles in the media. Tevogen Bio's average media sentiment score of 0.74 beat Lunai Bioworks' score of 0.26 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$9.50	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	$0.05	5.14

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 1,157.86%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Tevogen Bio is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tevogen Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Tevogen Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-610.37%
Lunai Bioworks	N/A	-1,243.45%	-360.31%

71.4% of Lunai Bioworks shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tevogen Bio beats Lunai Bioworks on 6 of the 11 factors compared between the two stocks.

How does Lunai Bioworks compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Senti Biosciences had 4 more articles in the media than Lunai Bioworks. MarketBeat recorded 9 mentions for Senti Biosciences and 5 mentions for Lunai Bioworks. Senti Biosciences' average media sentiment score of 1.08 beat Lunai Bioworks' score of 0.26 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Senti Biosciences has higher revenue and earnings than Lunai Bioworks. Senti Biosciences is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,572.57	-$61.44M	-$3.19	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	$0.05	5.14

Senti Biosciences currently has a consensus target price of $8.75, suggesting a potential upside of 766.34%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Senti Biosciences' return on equity of -425.72% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-425.72%	-94.70%
Lunai Bioworks	N/A	-1,243.45%	-360.31%

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Senti Biosciences beats Lunai Bioworks on 12 of the 15 factors compared between the two stocks.

How does Lunai Bioworks compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Polyrizon's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Lunai Bioworks	N/A	-1,243.45%	-360.31%

71.4% of Lunai Bioworks shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polyrizon had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 6 mentions for Polyrizon and 5 mentions for Lunai Bioworks. Polyrizon's average media sentiment score of 1.01 beat Lunai Bioworks' score of 0.26 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	$0.05	5.14

Polyrizon has a beta of -2.04, suggesting that its stock price is 304% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Summary

Polyrizon beats Lunai Bioworks on 5 of the 8 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$6.69M	$945.82M	$4.22B	$12.47B
Dividend Yield	N/A	4.84%	5.92%	5.28%
P/E Ratio	5.14	1.48	22.92	25.25
Price / Sales	N/A	115.93	162.73	77.32
Price / Cash	N/A	20.07	50.14	56.04
Price / Book	-0.21	8.22	38.26	6.91
Net Income	-$178.01M	-$3.77M	$113.55M	$334.11M
7 Day Performance	-22.06%	8.41%	2.60%	0.01%
1 Month Performance	-15.39%	62.24%	4.67%	1.17%
1 Year Performance	N/A	116.70%	16.53%	30.68%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.8533 of 5 stars	$0.26 -7.0%	N/A	N/A	$6.69M	N/A	5.14	20	Earnings Report Short Interest Increase
VIRI Virios Therapeutics	N/A	$1.65 +5.8%	N/A	-59.2%	$31.78M	N/A	N/A	5	Gap Down
SNSE Sensei Biotherapeutics	3.0684 of 5 stars	$23.40 -1.5%	$40.00 +70.9%	+193.5%	$31.38M	N/A	N/A	40	Trending News Earnings Report Analyst Downgrade Insider Trade
TVGN Tevogen Bio	2.0077 of 5 stars	$7.48 flat	$100.00 +1,236.9%	-86.2%	$31.15M	N/A	N/A	3	Earnings Report
SNTI Senti Biosciences	3.0876 of 5 stars	$0.99 +0.1%	$8.50 +762.2%	-67.8%	$30.70M	$22K	N/A	4	News Coverage Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. VIRI, SNSE, TVGN, SNTI, and PLRZ

How does Lunai Bioworks compare to Virios Therapeutics?

Summary

How does Lunai Bioworks compare to Sensei Biotherapeutics?

Summary

How does Lunai Bioworks compare to Tevogen Bio?

Summary

How does Lunai Bioworks compare to Senti Biosciences?

Summary

How does Lunai Bioworks compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. VIRI, SNSE, TVGN, SNTI, and PLRZ

How does Lunai Bioworks compare to Virios Therapeutics?

Does the media prefer VIRI or LNAI?

Is VIRI or LNAI more profitable?

Do institutionals and insiders believe in VIRI or LNAI?

Which has better valuation and earnings, VIRI or LNAI?

Which has more volatility & risk, VIRI or LNAI?

Do analysts recommend VIRI or LNAI?

Summary

How does Lunai Bioworks compare to Sensei Biotherapeutics?

Does the media favor LNAI or SNSE?

Do insiders & institutionals believe in LNAI or SNSE?

Which has stronger earnings & valuation, LNAI or SNSE?

Is LNAI or SNSE more profitable?

Which has more risk and volatility, LNAI or SNSE?

Do analysts rate LNAI or SNSE?

Summary

How does Lunai Bioworks compare to Tevogen Bio?

Does the media refer more to TVGN or LNAI?

Which has stronger earnings & valuation, TVGN or LNAI?

Do analysts recommend TVGN or LNAI?

Which has more volatility and risk, TVGN or LNAI?

Is TVGN or LNAI more profitable?

Do insiders and institutionals believe in TVGN or LNAI?

Summary

How does Lunai Bioworks compare to Senti Biosciences?

Does the media prefer SNTI or LNAI?

Which has preferable valuation and earnings, SNTI or LNAI?

Do analysts recommend SNTI or LNAI?

Which has more risk and volatility, SNTI or LNAI?

Is SNTI or LNAI more profitable?

Do institutionals and insiders have more ownership in SNTI or LNAI?

Summary

How does Lunai Bioworks compare to Polyrizon?

Is PLRZ or LNAI more profitable?

Do institutionals and insiders have more ownership in PLRZ or LNAI?

Do analysts recommend PLRZ or LNAI?

Does the media prefer PLRZ or LNAI?

Which has preferable valuation and earnings, PLRZ or LNAI?

Which has more risk and volatility, PLRZ or LNAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools